Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 50

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 50
---
 and other countries, protect trade secrets, and prevent others from infringing on our proprietary rights.

Since patent applications in the U.S. are maintained
in secrecy for at least portions of their pendency periods (published on U.S. patent issuance or, if earlier, 18 months from earliest
filing date for most applications) and since other publication of discoveries in the scientific or patent literature often lags behind
actual discoveries, we cannot be certain that we are or will be the first to make the inventions to be covered by our patent applications.
The patent position of biopharmaceutical and biotechnology firms generally is highly uncertain and involves complex legal and factual
questions. The U.S. Patent and Trademark Office has not established a consistent policy regarding the breadth of claims that it will allow
in biotechnology patents.

The patent applications we file, including applications
that will follow the filing of provisional patents, may not issue as patents or the claims of any issued patents may not afford meaningful
protection for our technologies, tests, or products. In addition, patents issued to us or to any future licensors may be challenged and
subsequently narrowed, invalidated, or circumvented. Patent litigation is widespread in the biotechnology industry and could harm our
business. Litigation might be necessary to protect our patent position or to determine the scope and validity of third-party proprietary
rights, and we may not have the required resources to pursue such litigation or to protect our patent rights.

Although we have executed assignment of invention
agreements with current scientific and technical employees and in the future will require our scientific and technical employees and consultants
to enter into broad assignment of invention agreements, and require all of our employees, consultants, and corporate partners with access
to proprietary information to enter into confidentiality agreements, these agreements may not be honored.

Diagnostic tests and therapeutic products we develop could be subject to infringement claims asserted by others.

We cannot assure that diagnostic tests and therapeutic
products based on our patents or intellectual property that we license from others will not be challenged by a third-party claiming infringement
of its proprietary rights. If we are not able to successfully defend patents that may be issued to us, that we may acquire, or that we
may license in the future, we may have to pay substantial damages or licensing fees, possibly including treble damages, for past infringement.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming, and ultimately unsuccessful.

Competitors may infringe our issued patents